MARKET

SWTX

SWTX

SPRINGWORKS THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.67
+0.55
+1.66%
After Hours: 33.67 0 0.00% 16:00 02/24 EST
OPEN
32.15
PREV CLOSE
33.12
HIGH
35.00
LOW
30.19
VOLUME
104.39K
TURNOVER
--
52 WEEK HIGH
40.50
52 WEEK LOW
17.02
MARKET CAP
1.41B
P/E (TTM)
-35.2086
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SWTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SWTX stock price target is 43.67 with a high estimate of 46.00 and a low estimate of 40.00.

EPS

SWTX News

More
  • SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
  • GlobeNewswire · 6d ago
  • What Company Will Eli Lilly Buy Next?
  • MotleyFool.com · 01/23 12:00
  • H.C. Wainwright Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $40
  • Benzinga · 01/21 12:53
  • Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
  • GlobeNewswire · 01/13 11:00

Industry

Pharmaceuticals
-2.84%
Pharmaceuticals & Medical Research
-2.86%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About SWTX

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for patient suffering from rare diseases and cancer. The Company has a portfolio of small molecule targeted oncology product candidates and other programs addressing genetically defined cancers. Its provides Nirogacestat, which is an oral, small molecule gamma secretase inhibitor (GSI). Nirogacestat is in development for the treatment of desmoid tumors. It also provides Mirdametinib, which is an oral, small molecule MEK inhibitor. Mirdametinib is in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). BGB-3245 is an investigational oral, selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions. Nirogacestat is in the Phase III DeFi clinical trial for the treatment of desmoid tumors.
More

Webull offers kinds of SpringWorks Therapeutics Inc stock information, including NASDAQ:SWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SWTX stock news, and many more online research tools to help you make informed decisions.